EP0964922A4 - Verfahren zur optimierung der gentherapie durch widerholtes sequenzmischen und selektion - Google Patents

Verfahren zur optimierung der gentherapie durch widerholtes sequenzmischen und selektion

Info

Publication number
EP0964922A4
EP0964922A4 EP97943600A EP97943600A EP0964922A4 EP 0964922 A4 EP0964922 A4 EP 0964922A4 EP 97943600 A EP97943600 A EP 97943600A EP 97943600 A EP97943600 A EP 97943600A EP 0964922 A4 EP0964922 A4 EP 0964922A4
Authority
EP
European Patent Office
Prior art keywords
optimization
selection
methods
gene therapy
recursive sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97943600A
Other languages
English (en)
French (fr)
Other versions
EP0964922A1 (de
Inventor
Willem P C Stemmer
Frederick C Christians
Shi-Kau Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Inc
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Publication of EP0964922A1 publication Critical patent/EP0964922A1/de
Publication of EP0964922A4 publication Critical patent/EP0964922A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP97943600A 1996-09-27 1997-09-26 Verfahren zur optimierung der gentherapie durch widerholtes sequenzmischen und selektion Withdrawn EP0964922A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72266096A 1996-09-27 1996-09-27
US3774296P 1996-09-27 1996-09-27
US37742P 1996-09-27
PCT/US1997/017300 WO1998013487A1 (en) 1996-09-27 1997-09-26 Methods for optimization of gene therapy by recursive sequence shuffling and selection
US722660 2000-11-28

Publications (2)

Publication Number Publication Date
EP0964922A1 EP0964922A1 (de) 1999-12-22
EP0964922A4 true EP0964922A4 (de) 2000-10-25

Family

ID=26714441

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97943600A Withdrawn EP0964922A4 (de) 1996-09-27 1997-09-26 Verfahren zur optimierung der gentherapie durch widerholtes sequenzmischen und selektion

Country Status (5)

Country Link
EP (1) EP0964922A4 (de)
JP (1) JP2001504325A (de)
AU (1) AU4503797A (de)
CA (1) CA2266423A1 (de)
WO (1) WO1998013487A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
DE69835360T2 (de) 1997-01-17 2007-08-16 Maxygen, Inc., Redwood City EVOLUTION Prokaryotischer GANZER ZELLEN DURCH REKURSIVE SEQUENZREKOMBINATION
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
WO1999021979A1 (en) 1997-10-28 1999-05-06 Maxygen, Inc. Human papillomavirus vectors
EP1690868A1 (de) 1997-10-31 2006-08-16 Maxygen, Inc. Modifizierung des Virustropismus und des Wirtspektrums durch virale Genomdurchmischung
US6468745B1 (en) 1998-01-16 2002-10-22 Large Scale Biology Corporation Method for expressing a library of nucleic acid sequence variants and selecting desired traits
US6303848B1 (en) 1998-01-16 2001-10-16 Large Scale Biology Corporation Method for conferring herbicide, pest, or disease resistance in plant hosts
US6426185B1 (en) 1998-01-16 2002-07-30 Large Scale Biology Corporation Method of compiling a functional gene profile in a plant by transfecting a nucleic acid sequence of a donor plant into a different host plant in an anti-sense orientation
US6500617B1 (en) 1998-05-01 2002-12-31 Maxygen, Inc. Optimization of pest resistance genes using DNA shuffling
IL140125A0 (en) 1998-06-17 2002-02-10 Maxygen Inc Method for producing polynucleotides with desired properties
EP1104459A1 (de) 1998-08-12 2001-06-06 Maxygen, Inc. Dna-shuffling von monooxygenase genen für die herstellung von industriellen chemikalien
CA2345203A1 (en) 1998-10-07 2000-04-13 Maxygen Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
GB9823468D0 (en) 1998-10-28 1998-12-23 Secr Defence Novel enzyme
AU1619400A (en) 1998-11-10 2000-05-29 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes
US6358712B1 (en) 1999-01-05 2002-03-19 Trustee Of Boston University Ordered gene assembly
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
EP1072010B1 (de) 1999-01-19 2010-04-21 Maxygen, Inc. Durch oligonukleotide-vermittelte nukleinsäuren-rekombination
KR20010102069A (ko) 1999-02-11 2001-11-15 추후제출 고효율 질량 분석
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
AU3879300A (en) * 1999-03-09 2000-09-28 Diversa Corporation End selection in directed evolution
MXPA02001513A (es) 1999-08-12 2002-07-02 Pfizer Prod Inc Gen de streptomyces avermitilis que dirige la relacion de avermectinas b2:b1.
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
GB9925161D0 (en) 1999-10-26 1999-12-22 Secr Defence Novel enzyme
WO2001038513A2 (en) * 1999-11-23 2001-05-31 Maxygen, Inc. Shuffling of agrobacterium and viral genes, plasmids and genomes for improved plant transformation
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
WO2001059071A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Methods of preparing and using a viral vector library
BR0108198A (pt) 2000-02-09 2003-03-25 Basf Ag ácido nucleico isolado, construção de gene, sequência de aminoácidos, vetor, organismo, anticorpo, molécula de ácido nucleico anti-sentido, processo para a preparação de pufas, óleo, lipìdeo ou ácido graxo ou uma fração destes, composição, uso da composição oleaginosa, lipìdica ou de ácido graxo, kit, e, processo para identificar um antagonista de elongases
US20010049104A1 (en) * 2000-03-24 2001-12-06 Stemmer Willem P.C. Methods for modulating cellular and organismal phenotypes
CN1328144A (zh) * 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——甲基化－dna－蛋白－半胱氨酸甲基转移酶10和编码这种多肽的多核苷酸
CA2411828A1 (en) 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules
WO2002000897A2 (en) 2000-06-23 2002-01-03 Maxygen, Inc. Novel chimeric promoters
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
IL154596A0 (en) 2000-08-25 2003-09-17 Basf Plant Science Gmbh Plant polynucleotides encoding novel prenyl proteases
AU2004260931B9 (en) 2003-04-29 2012-01-19 E.I. Du Pont De Nemours And Company Novel glyphosate-N-acetyltransferase (GAT) genes
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
EP1539960B1 (de) 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistente modifizierte interferon alpha polypeptide
ES2366830T3 (es) 2003-08-25 2011-10-25 Funzyme Biotechnologies Sa Nuevas proteínas fúngicas y ácidos nucelicos que codifican las mismas.
WO2005085431A2 (en) * 2004-03-02 2005-09-15 Epfl Ecole Polytechnique Federale De Lausanne Mutants of o6-alkylguanine-dna alkyltransferase
CA2735315A1 (en) 2004-06-09 2005-12-29 Pioneer Hi-Bred International, Inc. Plastid transit peptides
US7728118B2 (en) 2004-09-17 2010-06-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CA2990650C (en) 2008-05-23 2021-02-09 Pioneer Hi-Bred International, Inc. Novel dgat genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants
ES2706899T3 (es) 2008-09-26 2019-04-01 Tocagen Inc Vectores de terapia génica y citosina desaminasas
US8592649B2 (en) 2009-08-20 2013-11-26 Pioneer Hi Bred International Inc Functional expression of shuffled yeast nitrate transporter (YNT1) in maize to improve nitrate uptake under low nitrate environment
WO2011082304A1 (en) 2009-12-31 2011-07-07 Pioneer Hi-Bred International, Inc. Engineering plant resistance to diseases caused by pathogens
US8993837B2 (en) 2010-08-13 2015-03-31 Pioneer Hi-Bred International, Inc Chimeric promoters and methods of use
BR112014027468A2 (pt) 2012-05-04 2017-06-27 Du Pont polinucleotídeo isolado ou recombinante, construção de dna recombinante, célula, planta, explante vegetal, semente transgênica, polipeptídeo isolado, composição, métodos de produção de meganuclease, de introdução de rompimento e de integração de um polinucleotídeo.
BR112015023286A2 (pt) 2013-03-14 2018-03-06 Arzeda Corp polipeptídeo recombinante com atividade da dicamba descarboxilase, construto de polinucleotídeo, célula, método de produção de uma célula hospedeira compreendendo um polinucleotídeo heterólogo que codifica um polipeptídeo tendo atividade da dicamba descarboxilase, método para descarboxilar dicamba, um derivado de dicamba ou um metabolito de dicamba, método para a detecção de um polipeptideo e método para a detecção da presença de um polinucleotideo que codifica um polipeptideo tendo atividade da dicamba descarboxilase
US20140289906A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
WO2016040788A1 (en) 2014-09-11 2016-03-17 Promega Corporation Luciferase sequences utilizing infrared-emitting substrates to produce enhanced luminescence

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096548A (en) * 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9813487A1 *

Also Published As

Publication number Publication date
WO1998013487A1 (en) 1998-04-02
JP2001504325A (ja) 2001-04-03
EP0964922A1 (de) 1999-12-22
AU4503797A (en) 1998-04-17
CA2266423A1 (en) 1998-04-02

Similar Documents

Publication Publication Date Title
EP0964922A4 (de) Verfahren zur optimierung der gentherapie durch widerholtes sequenzmischen und selektion
EP0963434A4 (de) Methoden zur optimierung der gentherapie mittels rekursiven sequenzshufflings und selektion
PL331771A1 (en) Method of improving seeds
EP1027450A4 (de) Verfahren zum dna-shuffling
PL329870A1 (en) Dispersible macroparticles preparations as well as methods of obtaining and using them
PL333364A1 (en) Novel compounds and method of using them
AU9197898A (en) Resilient wrist support and therapeutic hand exerciser and method of manufacture
PL330847A1 (en) Plant gene of p-hydroxyphenylpyrogronianic dioxygenase
PL317930A1 (en) Oxalydine compounds, method of obtaining them and therapeutic agents
ZA977564B (en) Method of treatment
AU5605398A (en) Novel methods and compositions for treatment of autoimmune diseases
GB9715295D0 (en) Novel method of treatment
EP0933803A4 (de) Plasmabehandlungsmethode
GB9712866D0 (en) Novel method of treatment
AU6450398A (en) Sr-bi regulatory sequences and therapeutic methods of use
GB9707693D0 (en) Novel method of treatment
GB9715298D0 (en) Novel method of treatment
ZA971607B (en) Methods of treatment of allergic diseases
GB9715306D0 (en) Novel method of treatment
GB9618341D0 (en) Method of treatment
ZA973988B (en) Method of treatment
GB2294880B (en) Method of treating turf
AUPO124196A0 (en) Method of ground treatment
GB9602404D0 (en) Methods of treatment
AUPN925096A0 (en) Methods of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990415

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MAXYGEN, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20000907

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20031006

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040217